TY - JOUR
T1 - Siloxane Nanoprobes for Labeling and Dual Modality Functional Imaging of Neural Stem Cells
AU - Addington, Caroline P.
AU - Cusick, Alex
AU - Shankar, Rohini Vidya
AU - Agarwal, Shubhangi
AU - Stabenfeldt, Sarah
AU - Kodibagkar, Vikram
N1 - Funding Information:
The authors would like to acknowledge David Menn, Arizona State University, and Qingwei Liu, Barrow Neurological Institute, for technical assistance. These studies were supported by a Rising Stars in Engineering seed grant from College of Engineering, ASU (VDK and SES) and NIH 1DP2HD084067 (SES).
Publisher Copyright:
© 2015, Biomedical Engineering Society.
PY - 2016/3/1
Y1 - 2016/3/1
N2 - Cell therapy represents a promising therapeutic for a myriad of medical conditions, including cancer, traumatic brain injury, and cardiovascular disease among others. A thorough understanding of the efficacy and cellular dynamics of these therapies necessitates the ability to non-invasively track cells in vivo. Magnetic resonance imaging (MRI) provides a platform to track cells as a non-invasive modality with superior resolution and soft tissue contrast. We recently reported a new nanoprobe platform for cell labeling and imaging using fluorophore doped siloxane core nanoemulsions as dual modality (1H MRI/Fluorescence), dual-functional (oximetry/detection) nanoprobes. Here, we successfully demonstrate the labeling, dual-modality imaging, and oximetry of neural progenitor/stem cells (NPSCs) in vitro using this platform. Labeling at a concentration of 10 μL/104 cells with a 40%v/v polydimethylsiloxane core nanoemulsion, doped with rhodamine, had minimal effect on viability, no effect on migration, proliferation and differentiation of NPSCs and allowed for unambiguous visualization of labeled NPSCs by 1H MR and fluorescence and local pO2 reporting by labeled NPSCs. This new approach for cell labeling with a positive contrast 1H MR probe has the potential to improve mechanistic knowledge of current therapies, and guide the design of future cell therapies due to its clinical translatability.
AB - Cell therapy represents a promising therapeutic for a myriad of medical conditions, including cancer, traumatic brain injury, and cardiovascular disease among others. A thorough understanding of the efficacy and cellular dynamics of these therapies necessitates the ability to non-invasively track cells in vivo. Magnetic resonance imaging (MRI) provides a platform to track cells as a non-invasive modality with superior resolution and soft tissue contrast. We recently reported a new nanoprobe platform for cell labeling and imaging using fluorophore doped siloxane core nanoemulsions as dual modality (1H MRI/Fluorescence), dual-functional (oximetry/detection) nanoprobes. Here, we successfully demonstrate the labeling, dual-modality imaging, and oximetry of neural progenitor/stem cells (NPSCs) in vitro using this platform. Labeling at a concentration of 10 μL/104 cells with a 40%v/v polydimethylsiloxane core nanoemulsion, doped with rhodamine, had minimal effect on viability, no effect on migration, proliferation and differentiation of NPSCs and allowed for unambiguous visualization of labeled NPSCs by 1H MR and fluorescence and local pO2 reporting by labeled NPSCs. This new approach for cell labeling with a positive contrast 1H MR probe has the potential to improve mechanistic knowledge of current therapies, and guide the design of future cell therapies due to its clinical translatability.
KW - Cell-labeling
KW - Dual-modality imaging
KW - Fluorescence
KW - MR oximetry
KW - Nanoemulsions
KW - Neural progenitor/stem cells
KW - Polydimethylsiloxane
KW - Rhodamine
UR - http://www.scopus.com/inward/record.url?scp=84961165391&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84961165391&partnerID=8YFLogxK
U2 - 10.1007/s10439-015-1514-1
DO - 10.1007/s10439-015-1514-1
M3 - Article
C2 - 26597417
AN - SCOPUS:84961165391
SN - 0090-6964
VL - 44
SP - 816
EP - 827
JO - Annals of Biomedical Engineering
JF - Annals of Biomedical Engineering
IS - 3
ER -